The company’s preliminary results reveal a complex landscape of regional performance. While Staar reported robust momentum in China and double-digit growth across the Americas, the EMEA region faced a low-single-digit decline. Management attributed this weakness primarily to ongoing turmoil in the Middle East, noting that excluding those specific markets, the broader EMEA region actually posted double-digit gains.

Despite the immediate market reaction, the company remains up 26% year-to-date. Leadership cautioned that geopolitical and macroeconomic volatility remains a lingering risk, warning that broader instability could further impact future results. Staar Surgical is scheduled to provide a comprehensive breakdown of its quarterly performance on August 12.